7th Sep 2020 14:28
Avacta Group PLC - biotechnology company - Intends to launch an Elisa laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes Covid-19. Using the same affimer reagents that are incorporated into its rapid coronavirus saliva test being developed with Cytiva, Avacta said it has developed in-house a high performance Elisa laboratory test to detect the SARS-CoV-2 virus. Avacta plans to supply the SARS-CoV-2 spike protein Elisa reagent kit directly and is also in active discussions with potential partners and distributors globally.
Current stock price: 169.45 pence
Year-to-date change: multiplied from 18.50p
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group